Title: Maintenance therapy in multiple myeloma.
Authors: Harousseau, Jean-Luc
Abstract: The article discusses the maintenance therapy for multiple myeloma. It states that thalidomide is used as a maintenance therapy for patients with multiple myeloma (MM) which undergo autologous stem-cell transplantation (ASCT). It cites that Lenalidomide is more tolerated by patients than thalidomide after ASCT, but it is more myelotoxic than the latter. It notes that allogeneic stem-cell transplantation (allo-SCT) was already stopped because of its excessive toxicity in MM patients. It also mentions that maintenance treatment is not advisable for elderly patients to improve their overall survival (OS).
Subjects: MULTIPLE myeloma treatment; THALIDOMIDE; STEM cell transplantation; DRUG toxicity; DRUG efficacy; TOXICITY testing; OLDER patients; CANCER chemotherapy; TERATOGENIC agents
Publication: Hematology Reviews, 2009, Vol 1, Issue 2, p65
ISSN: 1970-6804
Publication type: Academic Journal
DOI: 10.4081/hr.2009.e12

Maintenance therapy in multiple myeloma.

Harousseau, Jean-Luc